| REVIEW ARTICLE |
|
| Year : 2016 | Volume
: 2
| Issue : 1 | Page : 3-12 |
|
|
Second-generation antihistamines
Pranjal Anil Mittal, Kiran V Godse, Sharmila P Patil
Department of Dermatology, DY Patil School of Medicine, Navi Mumbai, Maharashtra, India
Correspondence Address:
Pranjal Anil Mittal
OPD 54, DY Patil Hospital, Nerul, Navi Mumbai - 400 706, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2455-3972.184094
|
|
|
Clinical trials have proved the efficacy of antihistamines in the treatment of chronic idiopathic urticarial (CIU). Second-generation antihistamines are recommended as first-line therapy for CIU. This article reviews the newer second-generation antihistamines in light of recent advances in the understanding of their pharmacology, efficacy, and safety profile. A Google scholar search for second-generation antihistamines was done using the words “second generation H1antihistamines,” “bilastine,” “ebastine,” “olopatadine,” “rupatadine,” “levocetirizine,” “fexofenadine,” “desloratadine,” “histamine,” “allergy,” and “urticaria.” All the articles were retrieved and classified into review articles, studies, double-blinded trials, and case reports. The final data were then analyzed and presented in a narrative fashion. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
